Bildkälla: Stockfoto

Orphazyme: Negative CHMP Trend Vote - Redeye

We give our initial take on the likely rejection of Orphazyme’s EU filing for arimoclomol in Niemann-Picks disease type C.

We give our initial take on the likely rejection of Orphazyme’s EU filing for arimoclomol in Niemann-Picks disease type C.
Börsvärldens nyhetsbrev
ANNONSER